EN DE
Watch Jw Life Science Corp for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Jw Life Science Corp (234080) fair value: what the stock is really worth

As of Nov 19, 2026: fair value (intrinsic value) of Jw Life Science Corp stock KRW 30,641, price KRW 10,660, upside +187.4%, quality 61 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7234080000

JL Jw Life Science Corp logo Broad data Nov 15, 2026

Jw Life Science Corp

234080 · KO

Cheap (65% below fair value) and solid company, but falling price: meets 2 of 3 rules.

Follow free in the weekly email
Fair value 30,641 KRW · Strongly undervalued 
Quality 61/100 
Healthy Growth (revenue 5y +7.0 %/yr in KRW) 
Solidly profitable · 10.3% net margin (TTM) 
Low debt 
Generates free cash flow 
5.2% dividend yield · Well covered
Ranks above peers (12/14) 
Broad data 
Even on cautious assumptions the value is 80% above the price (19,221 KRW). 
Moderate moat 52/100 · thin data
Falling price (downtrend) 
Watch Jw Life Science Corp for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

16,021 KRW 9,444 KRW Fair Value 30,641 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.

How to read this chart

60‑month range 9,444 KRW – 16,021 KRW · fair‑value band 19,221 KRW – 39,833 KRW · the 10,660 KRW price screens below the 30,641 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.

Follow Jw Life Science in your weekly email

Every Wednesday you see whether Jw Life Science is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

JW Lifescience Corporation provides national infusion solutions in South Korea and internationally.

Show moreShow less

The company offers basic intravenous fluid that comprises water, electrolytes, and glucose; nutrient infusion solution that consist of nutrients, such as amino acids, lipids, proteins, vitamins, and minerals; and special infusion solutions.

The company was formerly known as JW Co. Ltd. and changed its name to JW Lifescience Corporation in April 2011. JW Lifescience Corporation was founded in 1994 and is based in Dangjin-si, South Korea.

Stock analysis

Jw Life Science Corp (234080) currently trades at 10,660 KRW, while our model-based Fair Value estimate is 30,641 KRW, implying the stock looks roughly 65% undervalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of 32,642 KRW per share, and 23 of the 26 models we run sit above the 10,660 KRW price.

Bear case: the Asset-Based group reads lowest at 6,209 KRW, and 3 of the 26 models stay below the price. Data coverage for this calculation is high.

Scenario range: 19,221 KRW (bear) to 39,833 KRW (bull), the price of 10,660 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 61/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Jw Life Science Corp reported revenue of 258B KRW in FY2025 versus 170B KRW in FY2021, a compound +11.0%/yr. Reported net income was 28.6B KRW in FY2025, compounding +22.0%/yr from FY2021.

Key figures

Market cap 165B KRW (≈ $124M) Micro · P/E ratio 6.3 · P/S ratio 0.65 · EPS (TTM) 1,680 KRW · Dividend yield 5.2% · Net margin 10.3% · Return on equity 11.9% · Return on assets (EBIT) 11.4% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).

What moves the price

The share trades about 27% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 187%, 234080 screens cheaper than that median.

Fair Value models

Bear 19,221 KRW Fair Value 30,641 KRW Bull 39,833 KRW
Price 10,660 KRW · Upside +187.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 11 months old). Earnings retained since then (1,000 KRW per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF 16,225 KRW 25,105 KRW 37,256 KRW 80
Growth DCF 16,147 KRW 24,284 KRW 34,876 KRW 78
Owner Earnings 17,996 KRW 27,762 KRW 41,127 KRW 76
All 26 models by family
DCF Models
FCF DCF 16,225 KRW 25,105 KRW 37,256 KRW 80
Owner Earnings 17,996 KRW 27,762 KRW 41,127 KRW 76
5Y Revenue Exit 16,779 KRW 28,292 KRW 43,259 KRW 71
5Y EBITDA Exit 24,195 KRW 42,698 KRW 64,950 KRW 74
5Y P/E Exit 21,857 KRW 38,156 KRW 55,850 KRW 70
10Y Revenue Exit 15,806 KRW 25,621 KRW 39,351 KRW 66
10Y EBITDA Exit 20,566 KRW 34,688 KRW 54,577 KRW 67
10Y P/E Exit 19,221 KRW 31,829 KRW 48,189 KRW 63
Earnings-Based
Graham-Dodd 12,562 KRW 46,748 KRW 63,187 KRW 64
Lynch FV 14,384 KRW 20,549 KRW 26,713 KRW 61
PEG = 1.0 14,384 KRW 20,549 KRW 26,713 KRW 57
EPV 12,179 KRW 13,944 KRW 15,397 KRW 74
Dividend Discount
Gordon GGM 3,702 KRW 6,450 KRW 8,632 KRW 68
DDM Multi-Stage 3,702 KRW 5,997 KRW 6,914 KRW 67
Multiples
P/E Multiple 30,482 KRW 40,642 KRW 50,803 KRW 63
P/S Multiple 23,554 KRW 31,405 KRW 39,257 KRW 58
P/B Multiple 15,876 KRW 21,168 KRW 26,460 KRW 55
EV/EBIT 24,754 KRW 33,878 KRW 43,003 KRW 66
EV/EBITDA 32,260 KRW 43,886 KRW 55,512 KRW 67
EV/Revenue 16,918 KRW 25,291 KRW 33,664 KRW 53
Asset-Based
NCAV (Graham) 4,634 KRW 6,209 KRW 9,268 KRW 54
Growth DCF
Growth DCF 16,147 KRW 24,284 KRW 34,876 KRW 78
Rev-Margin DCF 16,779 KRW 28,224 KRW 42,044 KRW 72
Economic Profit
Residual Income 12,553 KRW 14,143 KRW 18,561 KRW 76
ROIC Compounder 12,179 KRW 13,944 KRW 16,619 KRW 72
Growth Earnings
Growth-Adj P/E 21,449 KRW 30,641 KRW 39,833 KRW 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 61/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 52
How much profit the company makes from its sales and capital
Quality Growth 49
Are margins and returns getting better?
Cashflow 56
Do the profits arrive as real cash?
Financial strength 73
Debt, balance sheet and risk of trouble
Investment 54
Does it invest with discipline instead of growing at any price?
Low Volatility 86
How calm the share price moves, does not count
Price momentum 27
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 11
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 79/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+15.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.0%
Start year 2020 (pandemic). Over 10 years: +7.4% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.4%
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+16.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+11.6%
Dividend (yield on the price)5.2%
Profit margin 2019 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.18% → 13%

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−1.6%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about −3.6% a year for the price.

Watch 234080, get fair value alerts →

Compare Jw Life Science Corp with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 608 stocks

Beats the industry median on 12/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 61 · Above median
Fair Value upside +187.4% · Top 25%
Profitability
Return on equity (12 months) 11.9% · Above median
Return on assets 9.0% · Top 25%
Net margin (12 months) 10.3% · Above median
Operating margin (12 months) 14.8% · Above median
Growth and dividend
Revenue growth (quarter YoY) 1.6% · Below median
Dividend yield (12 months) 5.2% · Top 25%
Balance sheet
Debt / equity 0.15× · Above median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (12 months) 6.3× · Cheapest 25%
P/B 0.75× · Cheapest 25%
P/S (12 months) 0.65× · Cheapest 25%
Price / free cash flow (fiscal year) 6.1× · Cheapest 25%
EV/EBITDA 3.6× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 20
FUTURE (revenue growth)8 · sector 29
PAST (return on equity)48 · sector 26
HEALTH (low debt)93 · sector 96
DIVIDEND (yield)100 · sector 33

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $85.57 $113.53 +33% vs 234080
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥46.88 ¥52.43 +12% vs 234080
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,900 ₹1,983 +4% vs 234080
Haleon plc HLN $9.08 $8.47 −7% vs 234080
Merck KGaA MRK €148.40 €108.83 −27% vs 234080
Galderma Group GALD CHF 184.70 CHF 112.46 −39% vs 234080
Takeda Pharmaceutical Company TAK $21.27 $11.23 −47% vs 234080
Sandoz Group SDZ CHF 81.24 CHF 41.06 −49% vs 234080
Teva Pharmaceutical Industries Limited TEVA $42.23 $20.74 −51% vs 234080
Divi's Laboratories Limited DIVISLAB ₹11,178 ₹1,567 −86% vs 234080

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Jw Life Science Corp: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Jw Life Science Corp Fair Value". https://www.fairvalue-calculator.com/stock/234080

Frequently asked questions

Is Jw Life Science Corp (234080) overvalued or undervalued?
As of Nov 15, 2026, our model estimates a fair value of 30,641 KRW versus a price of 10,660 KRW, about +187% upside (undervalued).
What is the fair value of 234080?
Our model-based fair value for Jw Life Science Corp is 30,641 KRW (as of Nov 15, 2026), built from audited fundamentals. The current price: 10,660 KRW.
What is the quality score of 234080?
Jw Life Science Corp has a Quality Score of 61/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Jw Life Science Corp (234080)?
We do not set a price target; the yardstick is the fair value of 30,641 KRW (as of Nov 15, 2026) from 26 valuation models. Cautious scenario 19,221 KRW, optimistic scenario 39,833 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Jw Life Science Corp stock forecast for 2026?
Our models put fair value at 30,641 KRW, about +187% upside versus a price of 10,660 KRW (undervalued). Cautious scenario 19,221 KRW, optimistic scenario 39,833 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Jw Life Science Corp (234080)?
Jw Life Science Corp reported trailing-twelve-month revenue of about 254B KRW (latest available figure, as of Nov 15, 2026).
Does Jw Life Science Corp pay a dividend?
Jw Life Science Corp currently shows a dividend yield of 5.16% relative to its recent price (as of Nov 15, 2026).
How much is the dividend of Jw Life Science Corp (234080) and when is the ex-dividend date?
Jw Life Science Corp pays a dividend of 550.00 KRW per share a year, a dividend yield of 5.2%. The last ex-dividend date was Mar 31, 2026. The payout ratio is 32.7% of earnings. Free cash flow covers the dividend 3.18 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Jw Life Science Corp (234080)?
Today's price is already fair in a discounted-cash-flow model if free cash flow at Jw Life Science Corp shrinks by 1.6 % per year for five years (discount rate 11.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew 7.0 % per year. As of Nov 15, 2026.
What discount rate (WACC) does the fair value of 234080 use?
Our models discount Jw Life Science Corp at 11.6 %: a base by market capitalisation (micro), damped by beta 0.22, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Jw Life Science Corp that is -1.6 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.6 %) and the same formula as our fair value.
How much growth has Jw Life Science Corp (234080) delivered so far?
Over the past 5 years revenue at Jw Life Science Corp grew 7.0 % a year. The price currently implies free-cash-flow growth of -1.6 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Jw Life Science Corp (234080) growing?
The median revenue growth in the sector is +7.4 % a year. That is the yardstick for the growth priced into Jw Life Science Corp (-1.6 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Jw Life Science Corp (234080)?
The free-cash-flow yield on the price is 16.42 %: that much free cash flow Jw Life Science Corp produces per unit of market value. When it exceeds the discount rate of our models (11.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Jw Life Science Corp (234080)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Jw Life Science Corp it is 30,641 KRW per share (as of Nov 15, 2026), against a price of 10,660 KRW. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Jw Life Science Corp stock overvalued or undervalued in 2026?
As of Nov 15, 2026, 234080 trades below its calculated fair value: price 10,660 KRW, fair value 30,641 KRW, a gap of about +187% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 234080?
No. The price is what the market pays today (10,660 KRW); the fair value is what the company's own numbers justify (30,641 KRW). For Jw Life Science Corp the two are 19,981 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Jw Life Science Corp worth?
The market values Jw Life Science Corp at about 165B KRW (market capitalisation, as of Nov 15, 2026). Per share that is 10,660 KRW; our models calculate a fair value of 30,641 KRW per share.
What do the bullish and bearish scenarios say about 234080?
Our models span a range for Jw Life Science Corp: cautious scenario 19,221 KRW, base 30,641 KRW, optimistic 39,833 KRW per share (as of Nov 15, 2026, price 10,660 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 234080?
Jw Life Science Corp trades at a price-to-earnings ratio of 6.3 (as of Nov 15, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 30,641 KRW is built from several models across several years. Median P/E at fiscal year-end, 8 fiscal years (2018 to 2025), reported earnings: 13.4. Other multiples: P/B 0.8, P/S 0.7, EV/EBITDA 3.6.
How solid is the balance sheet of Jw Life Science Corp (234080)?
Balance-sheet figures for Jw Life Science Corp (as of Nov 15, 2026): return on equity 11.9%, debt of 0.15 per unit of equity. They feed the Quality Score of 61/100, which measures business quality independently of the share price.
How far is 234080 from its 52-week high?
Jw Life Science Corp trades at 10,660 KRW, about 27% below its 52-week high of 14,664 KRW and 2% above the low of 10,420 KRW (as of Nov 19, 2026). Distance from the high says nothing about value: that is what the fair value of 30,641 KRW is for.
Which stocks are comparable to Jw Life Science Corp?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Jw Life Science Corp stock attractive at the current price?
The data as of Nov 15, 2026: price 10,660 KRW, calculated fair value 30,641 KRW (+187%), Quality Score 61/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 234080 calculated?
We run Jw Life Science Corp through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 30,641 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 12.0% above its aggregate fair value. Jw Life Science Corp currently trades 65% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Jw Life Science Corp (234080)?
The closing price on Nov 19, 2026 was 10,660 KRW. Our model-based fair value is 30,641 KRW, about +187% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Jw Life Science Corp right now?
The price is below even our cautious bear case (19,221 KRW). The market is more pessimistic than our downside scenario. Solid quality (61/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (19,221 KRW to 39,833 KRW) leaves room in how you read the outcome.

Key figures of Jw Life Science Corp

How large is the market capitalisation of Jw Life Science Corp (234080)?
The market capitalisation of Jw Life Science Corp is 165B KRW (≈ $124M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Jw Life Science Corp (234080)?
The price-to-sales ratio of Jw Life Science Corp is 0.65 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Jw Life Science Corp (234080)?
Earnings per share at Jw Life Science Corp are 1,680 KRW (price ÷ EPS = P/E 6.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Jw Life Science Corp (234080)?
The dividend yield of Jw Life Science Corp is 5.2% (payout 32.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Jw Life Science Corp (234080)?
The net margin of Jw Life Science Corp is 10.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Jw Life Science Corp (234080)?
The return on equity (ROE) of Jw Life Science Corp is 11.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Jw Life Science Corp (234080)?
On an EBIT basis the return on assets of Jw Life Science Corp is 11.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Jw Life Science Corp (234080)?
The operating margin of Jw Life Science Corp is 14.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Jw Life Science Corp (234080)?
Revenue at Jw Life Science Corp is growing 1.6% versus a year earlier (3y avg +10.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Jw Life Science Corp (234080)?
Earnings per share at Jw Life Science Corp are down 28.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Jw Life Science Corp (234080) carry?
The net debt of Jw Life Science Corp is 40.6B KRW (fiscal year 2025, ≈ 1.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Jw Life Science Corp in the live analysis

One click puts Jw Life Science Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.